Chemomab to Present at Oppenheimer s Virtual Rare and Orphan Disease Summit
USA - English
Share this article
Share this article
TEL AVIV, Israel, May 12, 2021 /PRNewswire/ Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the company s CEO, Dr. Adi Mor will present a corporate update at Oppenheimer s virtual Rare and Orphan Disease Summit on May 21
st, 2021.
Webcast link may be accessed here.
The presentation will be available for 30 days following the event on the Company s investors section at the Chemomab website.
Operator
Good morning, everyone. My name is Leo and I ll be your conference operator. At this time, I d like to welcome everyone to Eagle Pharmaceuticals First Quarter 2021 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded today, May 10, 2021.
It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.
Lisa M. Wilson
Investor Relations
Thank you, Leo. Welcome to Eagle Pharmaceuticals first quarter earnings call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today s call are Eagle s Chief Executive Officer, Scott Tarriff; and Chief Financial Officer, Brian Cahill.
Operator
Good morning, ladies and gentlemen, and welcome to Lifetime Brands first-quarter 2021 earnings conference call. [Operator instructions] I would now like to introduce your host for today s conference. Andrew Squire. Mr.
Squire, you may begin.
Head, Investor Relations
Thank you. Good morning, and thank you for joining Lifetime Brands first-quarter 2021 earnings call. With us today from management are Rob Kay, chief executive officer; Larry Winoker, chief financial officer. Before we begin the call, I d like to remind you that our remarks this morning may contain forward-looking statements that relate to the future performance of the company.
And these statements are intended to qualify for the safe harbor liability established by the Private Securities Litigation Reform Act. Any such statements are not guarantees of future performance and factors that could influence our results are highlighted in today s press release and others are contained in our filings with the Se
Operator
Good day, and welcome to the Oasis Midstream Partners first-quarter earnings results conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference over to Richard Robuck, chief financial officer. Please go ahead.
Richard Robuck
Chief Financial Officer
Thanks, Sarah. Good morning, everyone. Today, we re reporting our first quarter of 2021 financial and operational results. We are delighted to have you on our call today.
I m joined by Taylor Reid and Michael Lou, as well as other members of the team. Please be advised that our remarks on both Oasis Petroleum and Oasis Midstream Partners, including the answers to your questions, include statements that we believe to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are subject to risks and uncertainties that could cause actual results to be materially different from those currentl
Operator
Good day everyone, and welcome to today s ANI Pharmaceuticals First Quarter 2021 Earnings Release Call. [Operator Instructions]
It s now my pleasure to turn the conference over to Lisa Wilson. Please go ahead.
Lisa M. Wilson
Investor Relations
Thank you, operator. Welcome to ANI Pharmaceuticals Q1 2021 earnings results call. This is Lisa Wilson of In-Site Communications, Investor Relations for ANI. With me on today s call are Nikhil Lalwani, President and Chief Executive Officer; and Stephen Carey, Chief Financial Officer of ANI. You can also access the webcast of this call through the Investors section of the ANI website at anipharmaceuticals.com.